共刺激分子B7.1在淋巴瘤组织中的表达

研究免疫共刺激分子Ｂ７．１在淋巴瘤组织中的表达及其在肿瘤免疫逃逸机制中的作用。     

伯基特淋巴瘤与EB病毒的关系及其p53和bcl-2蛋白的表达

目的 了解柏基特淋巴瘤和ＥＢ病毒的关系及ｐ５３和ｂｃｌ－２蛋白的表达。方法 采用ＰＣＲ、原位ＰＣＲ及免疫组化ＬＳＡＢ方法,检测了２８例伯基特淋巴瘤石蜡包埋的组织块。结果 发现８例ＥＢ病毒ＤＮＡ阳性,阳性率为２８．５％,８例阳性病例做了原位杂交,其中３例为阳性。２７例做了ｐ５３和ｂｃｌ－２免疫组化检测,生病例各为１２例（４４．４％）和１３例（４８．１％）。Ⅰ￣Ⅱ期和Ⅲ￣Ⅳ期ｐ５３和ｂｃｌ－２阳性病例     

石蜡包埋尤文瘤/外周原始神经外胚瘤中EWS-FLI1融合基因的表达

目的 运用逆转录聚合酶链反应(RT-PCR)技术检测石蜡包埋尤文瘤／外周原始神经外胚瘤(ES／pPNET)组织中特异性染色体易位融合基因EWS-FLI1／ERGmRNA的表达并探讨其诊断意义。方法 运用一步法RT-PCR技术检测25例石蜡包埋ES／pPNETs和15例其他小圆细胞肿瘤(包括8例胚胎型和腺泡型横纹肌肉瘤、4例低分化滑膜肉瘤、2例神经母细胞瘤和1例淋巴瘤)组织中EWS-FLI1／ERG的表达。结果 25例ES／pPNET中20例检测到EWS-FLI1／ERG融合基因的表达(8056),15例对照组均未检出EWS-FLI1的表达。结论 EWS-FLI1／ERGmRNA的表达是ES／pPNETs分子诊断的可靠指标,一步法RT-PCR是一种适用于临床常规石蜡包埋组织EWS-FLI1融合基因表达的检测方法。     

腮腺淋巴上皮瘤样癌与EB病毒感染的关系

目的：研究ＥｐｓｔｅｉｎＢａｒｒ 病毒（ＥＢＶ）与腮腺淋巴上皮瘤样癌（ｌｙｍｐｈｏｅｐｉｔｈｅｌｉｏｍａｌｉｋｅｃａｒｃｉｎｏｍａ,ＬＥＬＣ）的关系,并检测瘤细胞内ＥＢＶ 基因编码产物。方法：作者收集了中山医科大学所属病理科１９８６ 年１ 月至１９９５ 年１２ 月间３２ 例腮腺ＬＥＬＣｓ．。３２ 例ＬＥＬＣ石蜡包埋标本再次切片。采用免疫组化和原位核酸杂交法检测瘤细胞内ＥＢＶ 基因表达产物。结果：（１） 在１２５例腮腺癌中有３２ 例淋巴上皮瘤样癌,占总病例的２５－６％ （３２／１２５） 。（２）所有３２ 例腮腺ＬＥＬＣ组织中均有数量不等的ＥＢＮＡ１ 和ＥＢＥＲｓ 阳性瘤细胞。（３）２７ 例ＬＥＬＣ 组织中部分瘤细胞表达ＬＭＰ１ 。（４） 所有标本中均未见ＺＥＢＲＡ 阳性细胞。（５）３２例腮腺ＬＥＬＣ组织中ＥＡＤ、ＶＣＡ和ＭＡ的阳性表达率分别为７１－９ ％（２３／３２） 、６８－８ ％（２２／３２） 和１２－５％ （４／３２） 。结论：（１） 在鼻咽癌高发的广州地区,腮腺ＬＥＬＣ的发病率也较高。（２）腮腺ＬＥＬＣ 组织中均有ＥＢ病毒感染。（３）ＥＢ病毒在腮腺ＬＥＬＣ的感染主要为潜伏Ⅱ型,即表达ＥＢＮＡ１ 、ＥＢＥＲｓ 和ＬＭＰ１     

多聚酶链反应技术在NHL基因诊断中的应用研究

收集非何杰金淋巴瘤（ＮＨＬ）标本５９例。用全Ｔ（ＵＣＨＬ一１）与全Ｂ（Ｌ２６）ＭｃＡｂ作免疫组化分型。然后应用ｌｇＨ单轮和半重叠基因引物，Ｔ细胞受体β（ＴＣＲ＿β）基因引物进行多聚酶链反应（ＰＣＲ）扩增检测克隆性基因重排。检测阳性结果：新鲜组织ｌｇＨ７１．４％（１０．／１４），ＴＣＲ＿β８３．３％（１０／１２）。石蜡包埋组织ＩｇＨ（半重叠扩增）８０％（１２／１５），ＴＣＲ＿β７３．３％（１１／１５）。无假阳性。其中有６例有争议的疑难病例明确了诊断。结果表明ＰＣＲ技术是当前最特异、敏感而快速的ＮＨＬ克隆性基因重排检测方法。     

B7-1分子诱导体外抗肝癌免疫反应

目的：了解Ｂ７分子在体外抗肝癌免疫中的作用。方法：健康人外周血单个核细胞（ＰＢＭＣ）与ＨｅｐＧ２／ｈＢ７－１，ＨｅｐＧ２／ｎｅｏ及亲代ＨｅｐＧ２瘤苗混合培养（ＭＬＴＣ），检测淋巴细胞活化增殖能力，淋巴细胞ＨＬＡ－Ｉ类抗原的表达，培养上清ＩＦＮ－γ水平，ＴＮＦ活性及ＬＡＫ，ＣＴＬ细胞活性。结果：ＨｅｐＧ２／ｈＢ７－１瘤苗促淋巴细胞增殖最高达１４．６倍，明显高于ＨｅｐＧ２／ｎｅｏ和ＨｅｐＧ２瘤苗的作用     

肿瘤转移抑制基因nm23在良,恶性大肠组织中的表达及临？…

应用免疫组织化学方法对９６例大肠癌１２例大肠腺瘤７例幼年性息肉，６例增生性息肉，５６例癌旁粘膜及９例正常大肠粘膜组织ｎｍ２３／ＮＤＰＫ表达进行研究，结果在上述大肠组织中ｎｍ２３表达阳性率分别为９６．８％（９３／９６），９１．７％（１１／１２），８５．７％（６／７），１００％（６／６），８３．９％（４７／５６）和８８．９％（８／９），各组是差异无显著性，而在大肠癌中ｎｍ２３／ＮＤＰＫ常增强表达，分布     

EB病毒感染与中线恶性网织细胞增多症

使用一个针对ＥＢ病毒编码的小分子ＲＮＡ（ＥＢＥＲ）的寡核苷酸探针对１９例中线恶性网织细胞增多症病变组织进行了原位杂交检测，并配合免疫表型分析。结果为：（１）本组病例中１８／１９例（９４．７％）的病变组织中的异形淋巴样细胞表达Ｔ细胞分化抗原。ＣＤ３阳性１５例，ＵＣＨＬ１阳性９例，其中二者均阳性６例，但各例中的异形淋巴样细胞均未表达Ｂ细胞及组织细胞分化抗原；（２）ＥＢＥＲ原位杂交检测的阳性数高（１５／     

c—crbB—2,nm23蛋白产物在肺癌中的表达及意义

目的：研究肺癌组织中ｃ－ｅｒｂＢ－２、ｎｍ２３蛋白产物的表达情况及其临床意义。方法：应用免疫组织化学ＡＢＣ法，检测９２例手术切除的肺癌组织中ｃ－ｅｒｂＢ－２、ｎｍ２３蛋白产物的表达。结果：９２例肺癌中，ｃ－ｅｒｂＢ－２、ｎｍ２３蛋白产物阳性表达分别为６５例（７０．７％）、３８例（４１．３％）；且ｃ－ｅｒｂＢ－２阳性且与ｎｍ２３阳性组术后转移率分别高于其阴性组。另在４３例肺腺癌中ｃ－ｅｒｂＢ－２阳性     

淋巴母细胞性T细胞淋巴瘤与EB病毒的关系

目的：探讨淋巴母细胞性Ｔ细胞淋巴瘤与ＥＢ病毒的关系。方法：收集９例淋巴母细胞性Ｔ细胞淋巴瘤进行ＥＢ病毒检测，用免疫组织化学ＡＢＣ法证实其肿瘤细胞本质；用聚合酶链反应检测ＥＢ病毒特征性ＤＮＡ序列（ＥＢＶ ＤＮＡ）；用ＲＮＡ原位杂交法检测ＥＢ病毒编码的ＲＮＡ（ＥＢＥＲ１／２）。结果：９例淋巴母细胞性Ｔ细胞淋巴瘤，ＥＢＶ ＤＮＡ阳性７例（７７．８％），ＥＢＥＲ１／２阳性６例（６６．７％）。结论：淋巴母细     

Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors

Interleukin-12 (IL-12) promotes specific and long-lasting anti-tumor immunity mediated by T cells in a variety of murine tumor models. IL-12 also synergizes with B7.1 (CD80) co-stimulation to induce proliferation and cytokine production by both human and murine T cells in vitro. We evaluated the combined antitumor efficacy of IL-12 and B7.1 gene delivery in two apparently poorly immunogenic tumor models (TS/A and MCA207). In both of these models, expression of B7.1 and production of IL-12 in the inoculum led to improved anti-tumor immunity, with up to 80% long-term tumor-free animals (vs 0– 20% of mice remaining tumor free when inoculated with either B7.1- or IL-12-transfected tumors alone). Tumor-free mice were capable of rejecting a subsequent rechallenge with the wild-type tumor in 66% of the cases. Cooperativity was dependent upon the level of IL-12 secreted by engineered cells. IL-12 delivery required B7 expression of therapeutic effects to be observed in these models. Vaccines provided at a site distal to a control, non-transfected tumor slowed (TS/A) or abrogated (MCA207) the progression of wild-type tumors. The synergistic anti-tumor effects associated with combined application of B7.1- and IL-12-transfected tumors were partially negated by systemic administration of the CD28-B7.1/B7.2 antagonist CTLA4-Ig or by inoculation with neutralizing antibodies directed against murine interferon-γ or tumor necrosis factor-α, two cytokines elicited in response to IL-12 stimulation. These data support the potential clinical utility of combined gene therapy using IL-12- and B7.1-engineered autologous cells (tumor or fibroblasts) as a vaccine to elicit specific anti-tumor immunity.     

Genetic differentiation of poly I:C from B:9-23 peptide induced experimental autoimmune diabetes

Type 1 diabetes is an immune-mediated disease, in which T cells of the adaptive immune system mediate beta cell destruction. Recently the innate immune system has been linked to etiopathogenesis of several autoimmune diseases including type 1 diabetes, as innate effector cells (e.g. dendritic cells, monocytes/macrophages and NK cells) can prime and promote or regulate (auto)immune responses. We have previously developed an experimental autoimmune diabetes (EAD) model with insulin peptide B:9-23 immunization in transgenic H-2(d)mice expressing the costimulatory molecule B7.1 in their islets (under the Rat Insulin Promotor, RIP). We compared the induction of diabetes with polyinosinic-polycytidylic acid (Poly I:C), a mimic of double stranded viral RNA versus insulin B:9-23 peptide in mice following backcrossing of the B7.1 transgene on to BALB/c mice from original B7.1 C57Bl/6 mice. We find that diabetes induction by Poly I:C is C57Bl/6 associated, whereas B:9-23 peptide induced diabetes and induction of insulin autoantibodies (IAA) are dependent on BALB/c genes. This B:9-23 peptide induced diabetes is consistent with MHC class II H-2(d)being necessary for the response to this peptide. Of note Poly I:C induction of diabetes was lost while B:9-23 induction was retained with backcrossing to BALB/c mice. Interaction of genes and environment (antigenic epitope and viral mimic) can be important in the pathogenesis of immune mediated diabetes and activation of the innate immune system (e.g. Poly I:C) may be one key determinant.     

Differential immune response to B:9-23 insulin 1 and insulin 2 peptides in animal models of type 1 diabetes

Mice have two insulin genes that differ in the insulin sequence by two amino acids, including the B9 position. Given prior studies of the B:9-23 insulin peptide in NOD mice, a fundamental question is whether the immune response to the B:9-23 peptide of the two insulins is identical. We investigate responses to the immunization with B:9-23 insulin 1 and 2 peptides in NOD and RIP-B7.1 Balb/c mice. NOD and F1 (Balb/c x C57/Bl6) B7.1 transgenic mice were given either B:9-23 insulin 1, B:9-23 insulin 2 or tetanus toxoid (TT) control peptide. Insulin autoantibodies (IAA), and anti-B:9-23 antibodies (IgG1 and IgG2c) were measured. Subcutaneous injection of the insulin 2 but not the insulin 1 peptide significantly protected NOD mice from diabetes. Conceptually similar, insulin 1 peptide immunization accelerated diabetes in the B7.1 mice compared with insulin 2 peptide. Insulin 1 and 2 peptides induced similar levels of IAA in the NOD mice except at week 26, where insulin 2 induced higher levels of IAA. Anti-IgG1 B:9-23 peptide antibodies were higher in the insulin 2 immunized group of NOD mice, while IgG2c anti-B:9-23 peptide antibodies were higher in the insulin 1 group. Adoptive transfer of splenocytes from insulin 1 immunized mice to NOD.scid mice demonstrated accelerated diabetogenicity. The protection afforded by insulin 2 peptide but not insulin 1 peptide in the NOD mouse is reflected by its predominant Th2 humoral response. This may relate to the protection conferred by the insulin 1 knockout when bred onto NOD mice in contrast to acceleration of disease with an insulin 2 knockout.     

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease

PurposeTo investigate immune tolerance induction with transient low-dose methotrexate (TLD-MTX) initiated with recombinant human acid α-glucosidase (rhGAA), in treatment-naïve cross-reactive immunologic material (CRIM)-positive infantile-onset Pompe disease (IOPD) patients.MethodsNewly diagnosed IOPD patients received subcutaneous or oral 0.4 mg/kg TLD-MTX for 3 cycles (3 doses/cycle) with the first 3 rhGAA infusions. Anti-rhGAA IgG titers, classified as high-sustained (HSAT; ≥51,200, ≥2 times after 6 months), sustained intermediate (SIT; ≥12,800 and <51,200 within 12 months), or low (LT; ≤6400 within 12 months), were compared with those of 37 CRIM-positive IOPD historic comparators receiving rhGAA alone.ResultsFourteen IOPD TLD-MTX recipients at the median age of 3.8 months (range, 0.7–13.5 months) had a median last titer of 150 (range, 0–51,200) at median rhGAA duration ~83 weeks (range, 36–122 weeks). One IOPD patient (7.1%) developed titers in the SIT range and one patient (7.1%) developed titers in the HSAT range. Twelve of the 14 patients (85.7%) that received TLD-MTX remained LT, versus 5/37 HSAT (peak 51,200–409,600), 7/37 SIT (12,800–51,000), and 23/37 LT (200–12,800) among comparators.ConclusionResults of TLD-MTX coinitiated with rhGAA are encouraging and merit a larger longitudinal study.     

人TCA-12-2/TCB-7.1真核双表达载体的构建与表达

目的：将T细胞抗原受体基因TCA-12-2和TCB-7.1共同构建在真核表达载体pDC315，用于哺乳动物细胞293转染研究。方法： 将分离得到的淋巴细胞总RNA反转录合成cDNA,以此为模板进行PCR扩增得到TCA-12-2基因；以实验室保存含TCB-7.1基因的质粒为模板，扩增得到TCB-7.1基因。随后酶切，连入载体pIRES2-AcGFP1，通过亚克隆连入载体pDC315，得到重组质粒pDC315-TCA-12-2-TCB-7.1。重组体质粒经酶切鉴定后，并对插入的TCA-12-2和TCB-7.1基因片段进行测序，将鉴定好的阳性重组质粒用脂质体介导转染293细胞，并通过RT-PCR和流式细胞仪检测TCA-12-2和TCB-7.1基因的表达情况。结果： TCA-12-2和TCB-7.1可以同时构建在载体pDC315上，RT-PCR和流式细胞仪检测发现TCA-12-2和TCB-7.1基因可以成功在293细胞上表达。结论：成功构建了含TCA-12-2和TCB-7.1基因的双表达载体。     

Extrachromosomal recombination substrates recapitulate beyond 12/23 restricted VDJ recombination in nonlymphoid cells

V(D)J recombination occurs efficiently only between gene segments flanked by recombination signals (RSs) containing 12 and 23 base pair spacers (the 12/23 rule). A further limitation "beyond the 12/23 rule" (B12/23) exists at the TCRbeta locus and ensures Dbeta usage. Herein, we show that extrachromosomal V(D)J recombination substrates recapitulate B12/23 restriction in nonlymphoid cells. We further demonstrate that the Vbeta coding flank, the 12-RS heptamer/nonamer, and the 23-RS spacer each can significantly influence B12/23 restriction. Finally, purified core RAG1 and RAG2 proteins (together with HMG2) also reproduce B12/23 restriction in a cell-free system. Our findings indicate that B12/23 restriction of V(D)J recombination is cemented at the level of interactions between the RAG proteins and TCRbeta RS sequences.     

Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12/interleukin-23-deficient mice

We have previously shown that macrophages from interleukin (IL)-12p40 gene knockout (IL-12/IL-23-/-) mice have a bias towards the M2 activation profile, spontaneously secreting large quantities of transforming growth factor-beta1 (TGF-beta1) and producing low levels of nitric oxide (NO) in response to lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma). To verify whether the activation profile of dendritic cells (DCs) is also influenced by the absence of IL-12/IL-23, bone marrow-derived DCs from IL-12/IL-23-/- and C57BL/6 mice were evaluated. At first we noticed that approximately 50% of the C57BL/6 DCs were dead after LPS-induced maturation, whereas the mortality of IL-12/IL-23-/- DCs was < 10%, a protective effect that diminished when recombinant IL-12 (rIL-12) was added during maturation. Similarly to macrophages, mature IL-12/IL-23-/- DCs (mDCs) produced higher levels of TGF-beta1 and lower levels of NO than C57BL/6 mDCs. NO release was IFN-gamma-dependent, as evidenced by the poor response of IFN-gamma-/- and IL-12/IL-23-/-IFN-gamma-/- mDCs. Nevertheless, IFN-gamma deficiency was not the sole reason for the weak NO response observed in the absence of IL-12/IL-23. The high level of TGF-beta1 secretion by IL-12/IL-23-/- mDCs could explain why exogenous IFN-gamma partially restored the NO production of IFN-gamma-/- mDCs, while IL-12/IL-23-/- IFN-gamma-/- mDCs remained unresponsive. We also showed that CD4+ T-cell proliferation was inhibited by C57BL/6 mDCs, but not by IL-12/IL-23-/- mDCs. IFN-gamma and NO appear to mediate this antiproliferative effect because this effect was not observed in the presence of mDCs from IFN-gamma-/- or IL-12/IL-23-/- IFN-gamma-/- mice and it was attenuated by aminoguanidine. We conclude that the presence of IL-12/IL-23 during LPS-induced maturation influences the activation profile of DCs by a mechanism that is, only in part, IFN-gamma dependent.     

Influenza virus vaccination induces interleukin-12/23 receptor beta 1 (IL-12/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12/23R beta 1 or IFN-gamma receptor I

To investigate whether protective immune responses can be induced in the absence of normal interleukin-12/23/gamma interferon (IL-12/23/IFN-gamma) axis signaling, we vaccinated with the seasonal influenza virus subunit vaccine two patients with complete IL-12/23 receptor beta1 (IL-12/23R beta 1) deficiencies, two patients with partial IFN-gamma receptor I (pIFN-gamma RI) deficiencies, and five healthy controls. Blood samples were analyzed before, 7 days after, and 28 days after vaccination. In most cases, antibody titers reached protective levels. Moreover, although T-cell responses in patients were lower than those observed in controls, significant influenza virus-specific T-cell proliferation, IFN-gamma production, and numbers of IFN-gamma-producing cells were found in all patients 7 days after the vaccination. Interestingly, influenza virus-specific IFN-gamma responses were IL-12/23 independent, in striking contrast to mycobacterium-induced IFN-gamma production. In conclusion, influenza virus vaccination induces IL-12/23-independent IFN-gamma production by T cells and can result in sufficient humoral protection in both IL-12/23R beta 1- and pIFN-gamma RI-deficient individuals.     

Generation of a protective T-cell response following coronavirus infection of the central nervous system is not dependent on IL-12/23 signaling

The functional role of IL-12 and IL-23 in host defense and disease following viral infection of the CNS was determined. Instillation of mouse hepatitis virus (MHV, a positive-strand RNA virus) into the CNS of mice results in acute encephalitis followed by a chronic immune-mediated demyelinating disease. Antibody-mediated blocking of either IL-23 (anti-IL-23p19) or IL-12 and IL-23 (anti-IL-12/23p40) signaling did not mute T-cell trafficking into the CNS or antiviral effector responses and mice were able to control viral replication within the brain. Therapeutic administration of either anti-IL-23p19 or anti-IL-12/23p40 to mice with viral-induced demyelination did not attenuate T-cell or macrophage infiltration into the CNS nor improve clinical disease or diminish white matter damage. In contrast, treatment of mice with anti-IL-12/23p40 or anti-IL-23p19 resulted in inhibition of the autoimmune model of demyelination, experimental autoimmune encephalomyelitis (EAE). These data indicate that (1) IL-12 and IL-23 signaling are dispensable in generating a protective T-cell response following CNS infection with MHV, and (2) IL-12 and IL-23 do not contribute to demyelination in a model independent of autoimmune T-cell-mediated pathology. Therefore, therapeutic targeting of IL-12 and/or IL-23 for the treatment of autoimmune diseases may offer unique advantages by reducing disease severity without muting protective responses following viral infection.